- Dual-strength, MLFAE technology-enabled formulation helps deliver sustained 72-hour hydration for routine skincare and hyperkeratotic conditions
- Ideal for extreme dry skin and hyperkeratotic conditions such as psoriasis and ichthyosis, Ureaderm offers the next step in evidence-based, effective skin hydration.
Mumbai, May 13, 2025 –Emcutix Biopharmaceuticals Ltd., in collaboration with Canada-based Mantra Pharma Inc. – both subsidiaries of Emcure Pharmaceuticals Ltd. – has announced the pan-India launch of Ureaderm 10% & 20%, aurea-based moisturizer in cream formulation, for the prevention and management of extremely dry skin conditions and hyperkeratotic conditions such as psoriasis and ichthyosis, respectively. The moisturizer is designed to restore skin’s natural moisturizing factor and boost hydration levels.
| Product Portfolio & Key Attributes UREADERM 10% Cream Category: Topical emollient cream for routine skincare Indication: Daily restoration of skin’s natural moisturizing factor Star Ingredients: Urea 10%, Glycerine, Sodium Hyaluronate, Allantoin, Arginine, EPA, GLA, Jojoba Oil Benefit Profile: Rapid humectant action; enhances hydration and barrier resilience UREADERM 20% Cream Category: Topical therapeutic cream for hyperkeratotic conditions Indication: Adjunct management of ichthyosis, psoriasis, and severe xerosis Star Ingredients: Urea 20%, Arginine, Phytosterols, Allantoin, EPA, GLA, Glycerine, Jojoba oils Benefit Profile: Keratolytic efficacy; softens scale an |
Global studies have shown urea concentrations between 5% and 40% to be effective against dry skin conditions. Building on this scientific foundation, Ureaderm has been uniquely formulated to deliver enhanced and long-lasting hydration through the integration of advanced Multilayer Fatty Acid Emulsion (MLFAE) technology. This technology enables a sustained release of urea, ensuring deep hydration and continuous moisturization for up to 72 hours. In addition to urea, the formulation includes eicosapentaenoic acid (EPA), Gamma-linolenic acid (GLA) and allantoin, which work together to strengthen the skin’s lipid barrier, reduce water loss and keep skin soft, supple and healthy.
Available in two different concentrations, the 10% cream is ideal for adults looking for a regular skin care routine, while the 20% cream is suitable for people who need an extra dose of moisturizing to deal with skin conditions like ichthyosis or psoriasis, where extra keratolytic action is needed.
“We understand that modern skincare demands more than regular moisturising—they require formulations grounded in rigorous science with real-world efficacy. By integrating controlled-release encapsulation with optimized urea levels, the product ensures continuous skin barrier support that provides therapeutic benefits for conditions like ichthyosis and psoriasis,” sharesSathya Narayanan, CEO, Emcutix Biopharmaceuticals Ltd. “Above all, we remain committed to making performance-driven, evidence-based skincare solutions both accessible and affordable for consumers.”
About Emcutix Biopharmaceuticals Limited
Emcutix Biopharmaceuticals Ltd., backed by Emcure Pharmaceuticals Ltd., is a dermatology company committed to delivering innovative skincare and aesthetic solutions in India. Established in 2024, Emcutix aims to become a world-class leader by introducing groundbreaking treatments, globally recognized brands, and a differentiated product portfolio spanning therapeutic and aesthetic dermatology. The company is focused on introducing category-defining solutions that enhance patient outcomes and redefine care in Prescription, Consumer, and Aesthetic Dermatology. With a patient-centric approach, strong marketing expertise, and strategic partnerships with global leaders, Emcutix is set to redefine dermatological care and address unmet skincare needs across India.
Media Contact:
| Emcure Group | Adfactors PR |
| Naveen Soni – naveen.soni@emcure.com | Janhavi Bellare: +91 9322854508 |
| Arpita Halder – arpita.halder@emcure.com | Ankita Bandiwadekar: +91 8888700069 |
